8-K: Arbutus Biopharma Reports Q1 2024 Results, Provides Clinical and Corporate Update

Arbutus Biopharma announced its first quarter 2024 financial results, highlighted clinical trial progress, and provided updates on patent litigation and corporate strategy.

Summary

• Arbutus Biopharma reported a net loss of $17.9 million for the first quarter of 2024, compared to a net loss of $16.3 million for the same period in 2023.
• The company's total revenue decreased to $1.5 million from $6.7 million year-over-year, primarily due to reduced license and royalty revenue.
• Research and development expenses decreased to $15.4 million from $18.3 million, mainly due to the discontinuation of certain programs.
• As of March 31, 2024, Arbutus had $137.9 million in cash, cash equivalents, and investments, with an expected cash runway through the second quarter of 2026.
• The company expects its 2024 net cash burn to be between $63 million and $67 million, excluding proceeds from its at-the-market offering program.
• Clinical trials for imdusiran (AB-729) are progressing, with end-of-treatment data from two Phase 2a combination trials expected at the EASL Congress in June 2024.
• Preliminary data from the single-dose portion of the AB-101-001 clinical trial showed that AB-101 was generally well-tolerated and bound to the receptor target in healthy subjects.
• The company is also involved in ongoing patent infringement lawsuits against Moderna and Pfizer/BioNTech, with a trial date set for April 21, 2025, for the Moderna case.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the extended cash runway and progress in clinical trials, but tempered by the decreased revenue and ongoing losses. The positive court ruling is a good sign, but the litigation is still a risk.

Positives

• The company has a strong cash position with a runway extended through the second quarter of 2026.
• Clinical trials for imdusiran are progressing with promising data expected soon.
• AB-101, the oral PD-L1 inhibitor, has shown good tolerability and target engagement in early trials.
• The court ruling in the Moderna patent lawsuit was favorable to Arbutus.
• The company is actively advancing its pipeline of HBV assets.
• Arbutus is receiving licensing royalties from Alnylam's Onpattro.
• The company has a team with virology expertise and a proven track record.

Negatives

• The company experienced a decrease in revenue compared to the same period last year.
• The net loss for the quarter was $17.9 million.
• Research and development expenses, while decreased, still represent a significant cost.
• The company is involved in ongoing patent litigation, which can be costly and time-consuming.
• The company's net cash burn is expected to be between $63 million and $67 million for 2024.

Risks

• Clinical trials may not yield positive results or may be delayed.
• Regulatory approvals for product candidates may not be received.
• Economic and market conditions could worsen, impacting the company's financial position.
• Patent litigation outcomes are uncertain and could be unfavorable.
• The company may need to raise additional capital in the future.
• Collaborations may not realize expected benefits.
• Market shifts may require a change in strategic focus.

Future Outlook

Arbutus expects to present end-of-treatment data from multiple clinical trials at the EASL Congress in June 2024 and anticipates preliminary data from the multiple-ascending dose portion of the AB-101 trial in the second half of 2024. The company believes its current cash position will fund operations through the second quarter of 2026.

Management Comments

• Michael J. McElhaugh, Interim President and Chief Executive Officer, stated that the company continued to make progress in advancing its pipeline of HBV assets.
• Management believes an immune modulator plays an important role in the treatment regimen to functionally cure cHBV.
• Management believes that the company is well funded to move its existing clinical trials forward to achieve meaningful data and advance into a later stage clinical trial.

Industry Context

Arbutus is focused on developing a functional cure for chronic Hepatitis B, a significant unmet medical need. The company's approach involves combining antiviral and immunomodulatory therapies, which aligns with current trends in HBV treatment research. The company is competing with other pharmaceutical companies developing treatments for HBV, including those using RNAi and checkpoint inhibitors.

Comparison to Industry Standards

• Arbutus's approach to HBV treatment, combining RNAi therapeutics with immune modulators, is consistent with the industry's move towards combination therapies for complex viral infections.
• The company's imdusiran (AB-729) is comparable to other RNAi therapeutics in development for HBV, such as those from Arrowhead Pharmaceuticals and Dicerna Pharmaceuticals, though each has unique delivery mechanisms and targets.
• The development of an oral PD-L1 inhibitor (AB-101) is a novel approach compared to the more common antibody-based checkpoint inhibitors, potentially offering advantages in terms of administration and safety.
• The company's cash runway through Q2 2026 is a positive sign, indicating financial stability compared to some smaller biotech companies that may face more immediate funding challenges.
• The ongoing patent litigation against Moderna and Pfizer/BioNTech is a significant event, as it involves the use of LNP technology, which is also used by other companies such as BioNTech and CureVac.

Management Changes

Legal Proceedings

• Arbutus is involved in ongoing patent infringement lawsuits against Moderna and Pfizer/BioNTech.
• A trial date has been set for April 21, 2025, for the Moderna case.
• The court provided a claim construction ruling in the Moderna lawsuit, largely agreeing with Arbutus' position.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and the outcome of patent litigation.
• Employees may be affected by changes in the company's strategy and personnel.
• Patients with chronic HBV may benefit from the development of new treatments.
• The company's suppliers and partners may be impacted by the company's financial health and clinical trial progress.

Next Steps

• Present end-of-treatment data from Phase 2a trials at the EASL Congress in June 2024.
• Report preliminary data from the multiple-ascending dose portion of the AB-101 trial in the second half of 2024.
• Continue patient screening and enrollment in the AB-729-203 Phase 2a clinical trial.
• Continue fact discovery and expert reports in the patent litigation against Moderna.
• Advance the ongoing lawsuit against Pfizer/BioNTech.

Key Dates

Keywords

Hepatitis B, HBV, Imdusiran, AB-729, AB-101, RNAi, PD-L1 Inhibitor, Clinical Trials, Patent Litigation, Biopharmaceutical, LNP Technology